Added to YB: 2025-02-14
Pitch date: 2025-02-11
THRD [bullish]
Third Harmonic Bio, Inc.
+59.17%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.
Market Cap
$242.8M
Pitch Price
$3.38
Price Target
5.28 (-2%)
Dividend
N/A
EV/EBITDA
0.41
P/E
-4.32
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Third Harmonic Bio: Strategic Alternatives, Keeping Options Open on THB335
THRD: Biotech w/ promising Phase 1 data for THB335 (hives treatment). $155M market cap, $213M cash (6/30 est). 50% workforce cut, exploring strategic alternatives. Strong shareholders (Atlas, OrbiMed 25%). Possible reverse merger w/ CVR. Upside to $5.28 liquidation value.
Read full article (1 min)